SCHEMBL23725147

SCHEMBL23725147

O=Cc1ccn2c(=O)c(Br)cnc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 2/20 0.38
PKM P14618 1/20 0.38
GLA P06280 1/20 0.35
HPGD P15428 1/20 0.35
ALB P02768 1/20 0.33
MAPT P10636 4/20 0.32
DYRK1A Q13627 2/20 0.32
DYRK2 Q92630 2/20 0.32
DYRK1B Q9Y463 2/20 0.32
DYRK3 O43781 1/20 0.32
CCNT1 O60563 1/20 0.32
CDK9 P50750 1/20 0.32
CDK5 Q00535 1/20 0.32
CDK5R1 Q15078 1/20 0.32
NPSR1 Q6W5P4 2/20 0.31
LMNA P02545 1/20 0.31
KMT2A Q03164 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5905790 0.82 ALDH1A1 (0.36) ALDH1A1KDM4EGAAPKMDYRK1A
SCHEMBL23727510 0.78 KDM4E (0.40) ALDH1A1KDM4EGAAPKMGLA
SCHEMBL19533498 0.78 KDM4E (0.61) ALDH1A1KDM4EGAAPKMGLA
SCHEMBL25667222 0.77 ALDH1A1 (0.41) ALDH1A1KDM4EGAAPKMGLA
SCHEMBL3328465 0.76 DYRK1A (0.34) ALDH1A1KDM4EGAAPKMDYRK1A
SCHEMBL22595101 0.76 ALDH1A1 (0.38) ALDH1A1KDM4EGAAPKMGLA
SCHEMBL23725498 0.74 KDM4E (0.40) ALDH1A1KDM4EGAAPKMGLA
SCHEMBL23726165 0.72 ADORA3 (0.51) ALDH1A1KDM4EMAPT
SCHEMBL23725849 0.72 ALDH1A1 (0.38) ALDH1A1KDM4EGAAPKMGLA
SCHEMBL21273200 0.71 ADORA3 (0.50) ALDH1A1KDM4EGAAPKMGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP disclosed
CN-115413275-A Substituted 1,1 , -biphenyl compounds and methods of use thereof 爱彼特生物制药公司 2022-11-29 CN disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL ALDH1A1 172/4885KDM4E 224/4885GAA 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.